ArticleAmerican journal of cancer research2022

The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.

Chaoyuan Liu et al.PubMed ↗Full text ↗

No numbers read from the abstract.